GlassScriptPhysician profile
Mashour Yousef
NPI 1609893130
$945.10
in general payments reported to CMS, 2019-2025
19 companies · $503 in 2025
The $503 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $161 · 2022: $20.52 · 2023: $97.65 · 2024: $163 · 2025: $503.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $764.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $763.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $142.75 | 2023-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $122.81 | 2019 | |
| Novartis Pharmaceuticals Corporation | $90.30 | 2024-2025 | |
| Pfizer INC. | $89.31 | 2024-2025 | |
| Daiichi Sankyo INC. | $75.40 | 2024-2025 | Enhertu |
| Merck Sharp & Dohme LLC | $64.42 | 2024-2025 | Keytruda, Welireg, Lynparza |
| Janssen Biotech, INC. | $52.87 | 2025 | Darzalex, Tecvayli, Talvey |
| E.R. Squibb & Sons, L.L.C. | $33.79 | 2019-2022 | |
| Array Biopharma INC | $33.67 | 2024-2025 | Lorbrena, Mektovi, Tukysa |
| Celgene Corporation | $27.07 | 2024 | Reblozyl |
| Ipsen Biopharmaceuticals, INC | $26.70 | 2025 | Onivyde |
| Eisai INC. | $25.59 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.86 | 2025 | |
| Seagen INC. | $24.58 | 2019 | |
| Gilead Sciences, INC. | $24.38 | 2025 | Trodelvy |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $24.11 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.39 | 2025 | |
| Incyte Corporation | $20.27 | 2023 | Jakafi |
| Astrazeneca Pharmaceuticals LP | $19.83 | 2025 | Lynparza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mashour Yousef listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.